At GBS, we're focused on one and only one mission: to help talented entrepreneurs build great life science technology companies.

GBS Ventures achieves its 4th New Drug Approval from the US FDA

03 / 08 / 2020

> Read More

Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients

11 / 06 / 2020

> Read More

AbbVie Completes Transformative Acquisition of Allergan

08 / 05 / 2020

> Read More